← Back to Search

Control Blood Sampling for Complete Blood Count

N/A
Waitlist Available
Led By Brian Bales, MD
Research Sponsored by Vanderbilt University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time point 0 hour (at time of device insertion) and 8-22 hour (post device insertion)
Awards & highlights
No Placebo-Only Group

Summary

The goal of this study is to compare blood drawn using a device called HemoIV to standard-of-care blood drawn from a vein in the arm or from an IV catheter. The HemoIV is a device that is attached to an IV line. This device allows for blood to be drawn while a patient is receiving IV fluids. The main questions it aims to answer are: * Will the HemoIV device allow blood to be drawn without having to stop IV fluids? * Will the HemoIV device provide the same laboratory results as blood draws done by current standard practice? Participants will: * Receive standard medical procedures and/or treatment; * Have a HemoIV device inserted into their IV line in one arm; * Have an blood drawn twice from the HemoIV and from an IV line or needle stick from a vein in the other arm. The second blood draw will be done about 8-22 hours after the first blood draw; * Have the device removed after the second blood draw; * Receive a phone call about 8 days later to see how you are doing.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time point 0 hour (at time of device insertion) and 8-22 hour (post device insertion)
This trial's timeline: 3 weeks for screening, Varies for treatment, and time point 0 hour (at time of device insertion) and 8-22 hour (post device insertion) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Measurement of Alanine Transaminase (ALT) parameter equivalency with HemoIV to the control arm standard of care phlebotomy techniques.
Measurement of Albumin (ALB) parameter equivalency with HemoIV to the control arm standard of care phlebotomy techniques.
Measurement of Alkaline Phosphatase (AKP) parameter equivalency with HemoIV to the control arm standard of care phlebotomy techniques.
+29 more
Secondary study objectives
Study staff usability evaluation of blood sample collection from the HemoIV device.
Study staff usability evaluation of the ease of the IV solution infusion with the HemoIV device.
Study staff usability evaluation of the easy of the clearing of the blood channel with the HemoIV device
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: HemoIV Blood SamplingExperimental Treatment1 Intervention
Measurement of protocol specified blood parameters drawn from the HemoIV system
Group II: Control Blood SamplingExperimental Treatment0 Interventions
Measurement of protocol specified blood parameters drawn from the contralateral control arm

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor
900 Previous Clinical Trials
939,400 Total Patients Enrolled
MedTG LLCUNKNOWN
Brian Bales, MDPrincipal InvestigatorVanderbilt University Medical Center
~71 spots leftby Nov 2025